Substance use and its effect on antiretroviral treatment adherence among male fisherfolk living with HIV/AIDS in Uganda

Katelyn M. Sileo, Williams Kizito, Rhoda K. Wanyenze, Harriet Chemusto, Elizabeth Reed, Jamila K. Stockman, William Musoke, Barbara Mukasa, Susan M. Kiene

1 San Diego State University School of Public Health, San Diego, California, United States of America, 2 Mildmay Uganda, Lweza, Kampala, Uganda, 3 Makerere School of Public Health, Makerere University, Kampala, Uganda, 4 Division of Global Public Health in the Department of Medicine, University of California San Diego, La Jolla, California, United States of America

Current address: The Center for Interdisciplinary Research on AIDS at Yale University, New Haven, Connecticut
* katelyn.sileo@gmail.com

Abstract

Background

Fisherfolk are a most-at-risk population for HIV being prioritized for the scale up of HIV treatment in Uganda. Heavy alcohol use and potential drug use may be a major barrier to treatment adherence for men in this setting.

Objective

This study examines the prevalence of substance use, and its influence on antiretroviral treatment (ART) adherence, among male fisherfolk on ART in Wakiso District, Uganda.

Methods

This cross-sectional study included structured questionnaires (N = 300) with men attending HIV clinics near Lake Victoria. Using generalized logistic modeling analyses with a binomial distribution and logit link, we conducted multivariate models to test the association between each alcohol variable (quantity and frequency index, hazardous drinking) and missed pills, adjusting for covariates, and tested for interactions between number of pills prescribed and alcohol variables.

Results

Thirty-one percent of men reported sub-optimal adherence. Half (46.7%) reported drinking, of which 64.8% met criteria for hazardous drinking. Illicit drug use was low (6%). In the multivariate model, men with greater scores on the alcohol frequency and quantity index were more likely to report missed pills compared to those reporting no drinking (AOR: 1.60, 95% CI: 1.29–1.97). Hazardous drinking had a greater effect on missed ARV doses among men taking twice daily regimens compared to once daily (AOR: 4.91, 95% CI: 1.68–14.37).
Conclusions

Our findings highlight the need for targeted alcohol-reduction interventions for male fisherfolk on ART who drink at high quantities to improve ART adherence and to prevent the known negative health effects of alcohol for HIV-infected individuals.

Introduction

In Uganda and throughout sub-Saharan Africa, national strategies for HIV/AIDS prevention and control are increasingly centered on the scale up of antiretroviral treatment (ART). When taken as prescribed, antiretrovirals (ARVs) have the ability to reduce one’s viral load to non-infectious levels, which extends the life years of people living with HIV (PLHIV) substantially, and has the potential to curb the population-level incidence of HIV [1, 2]. In an effort to achieve universal access to treatment globally, the World Health Organization (WHO) has issued recommendations for the expansion of ART eligibility to all, regardless of CD4 cell count or disease stage [3]. The Ugandan Ministry of Health (MOH) is currently rolling out this policy, which has been in place for most-at-risk populations (MARPs) since 2014 [4]. In Ugandan fishing villages, HIV prevalence is estimated between 20–30% [5–7] compared to 5.9% nationally [8]. Thus, fisherfolk, or individuals living and working in the fishing communities on Lake Victoria, are a MARP being prioritized for test-and-treat initiatives [4, 9]. However, little is known about HIV care engagement with this population.

In order to achieve and sustain viral suppression and realize the full benefits of ART, it is necessary that PLHIV take 95% of their ARVs as prescribed [10]. In sub-Saharan Africa, men on ART have worse treatment adherence and greater mortality compared to women [11–13]. Men in fishing communities are likely to encounter even greater barriers to ART adherence than men generally—due to frequent travel, conflicting work responsibilities, distance and other structural barriers to HIV care [14, 15]. Further, high risk alcohol use and drug use observed in this setting [5, 9, 15–18] may pose a significant threat to men’s ART adherence. Substance use among PLHIV is a significant public health concern [19], as it can advance HIV/AIDS disease progression by directly decreasing CD4, and indirectly, through its effect on poor treatment adherence [20–23]. A meta-analysis of 40 studies reported alcohol drinkers were approximately 50–60% less likely to be classified as adherent, compared to those who abstained or drank relatively less [24].

Tumwesigye et al. [16] found 69.8% of fishermen drank at hazardous levels in two Ugandan fishing communities. Moreover, hazardous alcohol use, defined as a pattern of alcohol consumption that increases the risk of harmful consequences for the user and others [25], has been described in qualitative studies as part of the broader culture of fishermen [14]. Other drug use, including marijuana and khat (a plant-based stimulant) may also be high among fisherfolk [9, 18]; however, more data is needed on the prevalence of drug use in this setting. While alcohol use is reportedly high among fishing communities [5, 9, 15–18], and studies with fishermen identify alcohol use as a risk factor for HIV acquisition [5, 9, 18, 26] and a major barrier to prevention services and linkage to HIV care [27, 28], to our knowledge no research has examined the level and patterns of alcohol and drug use among fisherfolk living with HIV and on ART. Substance use may differ among PLHIV compared to the general population; some studies in Uganda report high rates of alcohol use and misuse among PLHIV [29], and others report temporary reductions in unhealthy drinking upon ART initiation, but a return to baseline drinking over time [30].
In this cross-sectional study, we examine the prevalence of substance use, as well as the role of substance use in HIV medication adherence among male fisherfolk on ART in Wakiso District, Uganda. We focused specifically on fisherfolk because we hypothesized that they would have unique barriers to HIV care engagement, including hazardous drinking, and we included only men based on evidence of a gender gap disadvantaging men in the HIV care continuum [11–13]. We test the associations between substance use and ART adherence, hypothesizing that those who drink and/or use drugs will have worse adherence. We also explore which risk levels of drinking may drive associations between alcohol use and adherence, and based on findings from prior studies [24, 31], explore the potential modifying effect of number of ARV pills prescribed on this relationship. This paper is the first to examine the prevalence of substance use, including alcohol and other drug use, and its effect on treatment adherence among Ugandan fisherfolk on ART. With fisherfolk a priority population for test-and-treat initiatives in Uganda and a key population in other African settings, research on substance use and treatment adherence could have important implications for the development of interventions to improve engagement in HIV care through substance use reduction for this most-at-risk population.

Methods

This cross-sectional study included a quantitative assessment conducted between October 2016 and March 2017 at seven health centers/outreach sites in Wakiso District, Uganda. Sites included three on land (Kasenyi outreach, Entebbe Hospital, Kigungu Health Centre III) and four on islands (Rapha Health Centre [Bussi Island], ZZinga outreach [ZZinga Island], Bussi Health Centre [Bussi Island], Kachanga outreach [Kachanga Island]). Rapha Health Centre is a private not-for-profit facility; Bussi HCIII, Kigungu, and Entebbe Hospital are governmental public health facilities. These clinics were purposively sampled because they are near fishing communities and therefore serve large populations of fisherfolk. Kasenyi, Kachanga, and ZZinga are outreach sites, which serve the surrounding landing sites and islands. We worked in collaboration with Mildmay Uganda in the implementation of the study, a non-governmental organization that partners with the Ugandan MOH to provide free HIV services to patients, including HIV testing, care, and treatment. Eligibility for ARVs at the time of the study was CD4 < 500 in the broader population in Uganda, but among fisherfolk and other MARPs, the MOH and Mildmay Uganda were implementing WHO recommendations for immediate initiation of ART upon diagnosis regardless of CD4 cell count or WHO clinical stage; in practice, this included same day initiation, except for men testing in community settings who initiated after linking to an HIV clinic.

The research population included male fisherfolk living with HIV/AIDS, including fishermen and other occupations supporting the fishing industry (fish sellers, boat loaders/operators). Our additional eligibility criteria were: aged 18 years or older and prescribed ART for at least 6 months (to measure adherence). Using purposive sampling, clinic staff and a trained research assistant recruited men for participation as they presented to the HIV clinic/outreach clinics during routine HIV appointments. Study staff non-systematically approached men to inform them about the study and assess their eligibility. We also invited men to participate during routine reminder calls for HIV clinic appointments. During calls, the research assistant informed men of the opportunity to participate in the study at their next appointment or to schedule an appointment at a time more convenient to them. A total of 64 men were recruited via telephone and participated at a future clinic appointment. Of the 322 eligible men invited to participate, 22 declined for the following reasons: did not have time (n = 14), did not want to disclose sensitive information (n = 4), intoxicated (n = 1), hearing impairment (n = 1),
wanted more compensation (n = 1), wanted to be interviewed with wife (n = 1). No additional data was collected from these men; therefore, we are unable to assess differences between eligible men who accepted vs. declined participation in this study.

Participants meeting eligibility criteria and providing written informed consent completed an interviewer-administered questionnaire immediately after enrolling in the study. The research assistant conducted the individual structured computer-based interviews (<45 minutes duration) in a private space in the HIV clinic or another agreed upon location. Participants received 10,000 Ugandan Shillings (~2.75 USD) to compensate them for their time in the structured interview. All procedures were approved by the institutional review boards at San Diego State University and Makerere University School of Public Health, as well as the Uganda National Council for Science and Technology.

Measures

**Covariates.** Among the socio-demographics and HIV-related variables measured, we include the following variables as potential covariates: age, education, monthly income, occupation, marital/partner status, research site, mobility, time spent traveling to the HIV clinic, time since HIV diagnosis, time since ART initiation, and number of pills prescribed per day. Based on the distribution of the data, several variables were dichotomized for analysis, including education (no schooling vs. any schooling), employment status (fishermen vs. other fishing occupations), marital status (married vs. not married/separated), research site (landing site vs. island), mobility (traveled/slept outside of the community in the prior year, yes or no), and number of pills prescribed per day (once daily vs. twice daily). Continuous variables included monthly income (1 unit equates to 50,000 shillings), time spent traveling to the HIV clinic (1 unit equates to 30 minutes), and time on ART and since diagnosis (1 unit equates to 6 months).

**Alcohol variables.** We used the WHO’s Alcohol Use Disorders Identification Test (AUDIT) to assess drinking risk levels [32] (present sample, \( \alpha = 0.63 \)). The AUDIT includes cut-off scores to categorize individuals at different levels of risky drinking, which we use for data analysis, including: hazardous alcohol use (score of 8 or more), high risk or harmful use (16–19), and dependence (20 or more) [25]. By taking the product of the first two AUDIT items assessing frequency and quantity of alcohol use, we also calculated an index of current drinking frequency and quantity; this measure weighs the quantity of alcohol typically consumed by frequency of use and is a more proximal measure to current drinking than the AUDIT risk categories, which asks about the prior year. In addition, we assessed the type of alcohol typically consumed. Response options included alcoholic beverages common in the study setting: bottled beer (4.5–7% alcohol by volume [ABV]), tonto (locally brewed fermented banana juice, 3% ABV), malwa (locally brewed from millet, communally shared in single container with straws, 3% ABV), Waragi (traditional gin, 48.4% ABV), “other kind of local brew,” and “other kind of alcohol.”

**Other drug use variables.** Drug use was assessed by the National Institute of Drug Abuse (NIDA) Modified ASSIST scale [33], adapted for the Ugandan context. Participants were asked about their lifetime use of substances, use within the prior 3 months, and the extent of use for each type of drug reported in the prior 3 months. We included all drugs in the original NIDA ASSIST, adapted to include the Lugandan (local language) and local names for each. Drugs included: cannabis, cocaine, prescription stimulants, methamphetamine, inhalants, sedatives or sleeping pills, hallucinogens, street opioids, prescription opioids, and tobacco. We added substances specific to Uganda, derived from consultation with Ugandan experts in drug use, and the piloting of items locally, including: kuber (a plant-based stimulant, chewed or
consumed as a tea), shisha (a plant-based stimulant, commonly smoked with marijuana), and khat (a plant-based stimulant, chewed).

**Adherence outcome.** The Adult AIDS Clinical Trial Group (AACTG) scale was used to measure self-reported ARV adherence [34]. The AACTG includes recall questions about ARVs missed for the previous four days prior to the interview and items measuring reasons for non-adherence. It has demonstrated construct validity in Uganda and similar settings [35]. For analysis, we assess the proportion of missed ARVs in the prior four days, out of total ARVs prescribed. In addition to self-reported adherence, we documented initiation date, and ART regimen from participants’ medical records. See S1 File for a copy of the study measures.

**Data analysis plan.** In SPSS version 24, we characterize the prevalence of alcohol and other substance use using descriptive statistics. We identified outliers (values greater than 3 standard deviations [SD] outside of the mean) [36] and truncated them to the highest value within 3 SDs of the mean for the following variables: monthly income, months since diagnosis, months on ART, and minutes traveled to the clinic. We used generalized logistic modeling analyses with a binomial distribution and logit link with our outcome in the form of events within trials, with events being the number of missed ARVs and trials being the number of ARVs prescribed over a four-day recall period (possible range given regimens prescribed was 4–8). We tested bivariate associations between potential independent variables, including socio-demographic and HIV variables (age, education, monthly income, occupation, marital/partner status, research site, mobility, time spent traveling to the HIV clinic, time since HIV diagnosis, time since ART initiation, number of pills prescribed) and missed pills, to determine which variables to include in the final models. We also planned to test the bivariate associations between the quantity and frequency index and drinking by AUDIT risk categories (risky drinking, hazardous, dependent) with missed pills, contingent on prevalence. Finally, we tested separate multivariate models for each alcohol variable (AUDIT risk categories, quantity and frequency index) associated with missed pills (p < 0.10 in bivariate models), adjusting for statistically significant covariates (p < 0.10), and testing for interactions between number of pills prescribed and alcohol variables. Odds Ratios (OR) and Adjusted Odds Ratios (AOR) from bivariate and multivariate analysis with 95% confidence intervals are presented. In multivariate models, we drop covariates that lost statistical significance (p < 0.10), presenting only the trimmed models. We planned to mirror the analyses described for alcohol, with the drug use variables, dependent on sufficient prevalence among the sample.

**Results**

**Participant characteristics**

The average age of our full sample (N = 300) was 37 (SD = 8.6), and most men reported being employed as a fisherman (82%) and never attending school (67.3%). On average, men had been aware of their status for about two years (mean = 24.6 months, SD = 17.8) and were initiated on ART soon after diagnosis (mean = 22.9 months, SD = 13.5). Men reported taking 87.8% (SD = 21.5%) of their ARV pills over the 4-day recall period, making 69% of the sample adherent (using a criterion for optimal adherence of 95% of pills taken as prescribed), and about a third of the sample was sub-optimally adherent (31%). See Table 1 for more details on sample characteristics.

**Prevalence of alcohol use**

Approximately half of men reported drinking in the prior year (47.3%) as well as in the prior 30 days (46.7%). Tonto (30.3%) and Waragi (24.6%) were the most commonly consumed drinks. Men reported an average of almost 3 drinks per drinking day for beverages other than
Table 1. Participant characteristics, alcohol and other substance use, Uganda 2016–2017, N = 300.

| Demographics | n (%) | Mean | SD  | Range |
|--------------|-------|------|-----|-------|
| Age          | 36.9  | 8.6  |     | 20–70 |
| Education    |       |      |     |       |
| No schooling | 202 (67.3%) |     |     |       |
| Primary level| 84 (28.0%)  |     |     |       |
| Secondary level| 14 (4.7%) |     |     |       |
| Marital status|        |      |     |       |
| Never married| 30 (10.0%)  |     |     |       |
| Divorced     | 78 (26.0%)  |     |     |       |
| Widowed      | 16 (5.3%)   |     |     |       |
| Married & separated most of the time | 29 (9.7%)  |     |     |       |
| Married & living together most of the time | 147 (49.0%) |     |     |       |
| Monthly income (converted to USD) | 62.2 | 29.7 | 4.1–160.4 |
| Occupation   |       |      |     |       |
| Fishermen    | 246 (82.0%) |     |     |       |
| Fish seller, cleaner, dryer | 35 (11.7%)  |     |     |       |
| Boat operator, repairer, loader, other | 19 (9.7%)    |     |     |       |
| Mobility (frequency of travel in prior 12 months) |       |      |     |       |
| No travel    | 106 (35.3%) |     |     |       |
| Once         | 73 (24.3%)  |     |     |       |
| 2–5 times    | 91 (30.3%)  |     |     |       |
| 6 or more times | 30 (10.0%) |     |     |       |
| Travel time to clinic (minutes) | 41.4 | 39.56 | 2–180 |
| HIV/AIDS variables |       |      |     |       |
| Months since HIV diagnosis | 24.6 | 17.8 | 4–102 |
| Months since ART initiation | 22.9 | 13.5 | 2–55 |
| Treatment regimen* |       |      |     |       |
| First line regimen | 298 (99.3%) |     |     |       |
| TDF+3TC+EFV (Preferred) | 260 (87.2%) |     |     |       |
| AZT+3TC+EFV | 11 (3.7%)   |     |     |       |
| AZT+3TC+NVP | 24 (8.0%)   |     |     |       |
| TDF+3TC+NVP | 3 (1.0%)    |     |     |       |
| Second line regimen | 2 (0.7%) |     |     |       |
| TDF/3TC     | 1 (50.0%)   |     |     |       |
| AZT+3TC     | 1 (50.0%)   |     |     |       |
| Number of pills prescribed per day |       |      |     |       |
| Once daily dosing | 260 (86.7%) |     |     |       |
| Twice daily dosing | 40 (13.3%) |     |     |       |
| ART Adherence (% of prescribed pills taken) | 87.8% | 21.5% | 0–100% |
| Sub-optimal adherence (< 95% of pills taken as prescribed) |       |      |     |       |
| Yes          | 93 (31.0%)  |     |     |       |
| No           | 207 (69.0%) |     |     |       |
| Alcohol use  |       |      |     |       |
| Type of alcohol typically consumed* |       |      |     |       |
| Ttonto       | 43 (30.3%)  |     |     |       |
| Waragi       | 35 (24.6%)  |     |     |       |
| Malwa        | 28 (19.7%)  |     |     |       |
Among those reporting any alcohol use, 40% of those who drink reported ever binge drinking, though infrequently (2.1% at least once/week, 9.2% at least once/month, 23.9% less than once/month). Among men reporting any drinking, the number of drinks typically consumed on drinking days was 2.92 (SD = 1.54, range 1–10), which we adjusted based on the alcohol content and serving size of the type of alcohol they reported most typically consuming [37], with the exception of malwa which does not come in a standardized container and is difficult to measure consumption volume because it is consumed communally.

The average AUDIT score was 4.5 (SD = 5.13), and nearly a third (30.7%) of the sample met criterion for hazardous drinking (AUDIT score ≥ 8) in the prior year; among those reporting any drinking, two-thirds drank at hazardous levels (64.8%). Only eight men met AUDIT criterion of high-risk drinking (AUDIT ≥ 16), and one for alcohol dependence (AUDIT ≥ 20). Descriptive statistics for alcohol use are displayed in Table 1.

### Prevalence of drug use, excluding alcohol

Only 6% of the sample reported ever using drugs other than alcohol, and only 3% reported using prescription drugs for non-medical reasons. Among the 18 men who reported any drug use, 6% reported using any other kind of local brew, and only 1% reported using any other kind of alcohol.

---

Table 1. (Continued)

| Subcategory                                                                 | n (%) | Mean  | SD    | Range |
|-----------------------------------------------------------------------------|-------|-------|-------|-------|
| Bottled beer                                                                | 26 (18.3%) |       |       |       |
| Any other kind of local brew                                               | 8 (5.6%) |       |       |       |
| Any other kind of alcohol                                                  | 1 (1.4%) |       |       |       |
| Alcohol quantity (drinkers only)*                                          |       | 2.92  | 1.54  | 1–10  |
| AUDIT score                                                                |       | 4.5   | 5.1   | 0–20  |
| AUDIT score (drinkers only)*                                               |       | 9.0   | 3.9   | 2–20  |
| Hazardous alcohol use (AUDIT = /≥ 8)                                       |       | 92 (30.7%) |     |       |
| Hazardous alcohol use (AUDIT = /≥ 8) (drinkers only)*                      |       | 92 (64.8%) |     |       |
| High risk alcohol use (AUDIT = /≥ 16)                                     |       | 8 (2.7%) |       |       |
| Alcohol dependence (AUDIT = /≥ 20)                                        |       | 1 (0.30%) |       |       |

### Drug use (excluding alcohol)

#### Prescription drug use for non-medical reasons (ever)

- **Yes**: 9 (3.0%)
- **No**: 291 (97.0%)

#### Illicit drug use (ever)

- **Yes**: 18 (6.0%)
- **No**: 282 (94.0%)

#### Drugs used (ever)

- **Cannabis**: 2 (0.70%)
- **Tobacco**: 15 (5.0%)
- **Kuber (stimulant)**: 7 (2.3%)
- **Sisha (stimulant)**: 5 (1.7%)
- **Khat (stimulant)**: 3 (1.0%)

Note: Adherence calculated based on the proportion of pills taken over a four day recall period of total pills prescribed, based on the Adult AIDS Clinical Trial Group (AACTG) scale (Chesney et al., 2000); * indicates items assessed only among participants reporting alcohol consumption in the prior 12 months (n = 142); alcohol quantity = number of drinks typically consumed on drinking days; AUDIT = Alcohol Use Disorder Identification Test (World Health Organization, 2001); variables calculated from AUDIT score assess alcohol use in the prior year; Tonto is a locally brewed fermented banana juice, 3% volume/volume percent (v/v), malwa is locally brewed from finger millet, communally shared in single container with straws, 3% v/v; Waragi is traditional gin, 48.4% v/v.

https://doi.org/10.1371/journal.pone.0216892.t001
use other than alcohol, illicit substances included kuber (n = 7), sisha (n = 5), khat (n = 3), and Cannabis (n = 2); tobacco use was also reported (n = 15). Table 1 includes descriptive statistics for drug use. Due to the low use of other drugs, we focus the remainder of the findings on alcohol use.

Effect of alcohol use on ART adherence

In bivariate and multivariate analyses, we operationalized alcohol use in two ways: alcohol use quantity/frequency index and hazardous alcohol use (AUDIT ≥ 8) (yes or no). For hazardous alcohol use, we pooled no drinking and low risk drinking together as the reference group, as the mean adherence percentage demonstrated no difference in adherence levels between no drinking and low risk drinking (AUDIT = 1–7) (mean adherence for non-drinkers = 88.49%, for low risk drinkers = 88.70%). In addition, we did not separate the AUDIT categories of high-risk/harmful drinking (AUDIT ≥ 16) or alcohol dependence (AUDIT ≥ 20) for analysis due to their low prevalence in the prior year according to the AUDIT.

In unadjusted models, greater scores on the alcohol use quantity and frequency index was positively associated with greater odds of reporting missed ARVs (OR: 1.56, 95% CI: 1.27–1.92, p < 0.001). Compared to no drinking or low risk drinking (AUDIT = 1–7), men meeting criteria for hazardous alcohol use (AUDIT ≥ 8) had a 1.39 (95% CI: 0.98–1.98) greater odds of non-adherence; however, the effect was marginally significant (p = 0.06). Covariates found statistically associated with missed pills (p < 0.10) in bivariate models included: younger age, greater education, lower monthly income, mobility in the prior 12 months, greater travel time to HIV clinic, and being prescribed a once daily (ART) regimen (compared to twice daily). See Table 2 for detailed statistics.

In the final trimmed model testing the association between the alcohol use quantity and frequency index and missed ARVs adjusted for covariates (see Table 3), a positive main effect remained, with greater scores on the alcohol use quantity and frequency index positively associated with greater odds of reporting missed ARVs (AOR: 1.60, 95% CI: 1.29–1.97, p < 0.001). Negative main effects for younger age and number of pills prescribed also remained in the final model, with decreased odds of missed ARVs greater among older men (AOR: 0.97, 95% CI: 0.94–0.99, p < 0.001) and men taking twice daily regimens (compared to once daily) (AOR: 0.43, 95% CI: 0.25–0.74, p = 0.02). We also found men with any education had greater likelihood of missed ARVs compared to no education (AOR: 1.51, 95% CI: 1.06–2.14, p = 0.02). A marginally significant negative association remained for monthly income (AOR: 0.73, 95% CI: 0.51–1.04, p = 0.09). No statistically significant interaction was identified between the alcohol index and number of pills prescribed.

Table 4 displays the final trimmed multivariate model testing the association between hazardous drinking and ART adherence, adjusted for covariates. The main effect between hazardous drinking and missed ARVs was not statistically significant in the full model (AOR: 1.10, 95% CI: 0.75–1.61, p = 0.63). Younger age (AOR: 0.96, 95% CI: 0.94–0.99, p = 0.002), any education compared to no education (AOR: 1.54, 95% CI: 1.08–2.18, p = 0.02), and taking a twice-daily regimen compared to once daily (AOR: 0.26, 0.12–0.55, p < 0.001) remained significantly associated with missed pills in the full model. There was a statistically significant interaction between hazardous alcohol consumption and number of pills prescribed; men taking twice daily dosing and reporting hazardous alcohol use were nearly five times as likely to report missed ARVs than men taking twice daily dosing but reporting no hazardous alcohol use (AOR: 4.91, 95% CI: 1.68–14.37, p = 0.004); see Table 4 for statistics and Fig 1 for a graphic depiction of the observed interaction.
Despite PLHIV in fishing communities being prioritized for the scale up of test-and-treat initiatives in Uganda, little is known about substance use in this population or its effect on optimal ART adherence; this is the first study to our knowledge to begin to fill this gap in the literature. Among our sample of men enrolled in HIV care, approximately a third reported sub-optimal ART adherence (<95% of ARVs taken as prescribed). Though half the sample reported abstaining from alcohol use altogether, a third of men met criteria for “hazardous” table.

Table 2. Bivariate associations between independent variables and missed antiretroviral medication, Uganda 2016–17, N = 300.

| Demographics and HIV variables | OR (95% CI) | x²   | p    |
|--------------------------------|-------------|------|------|
| Age                           | 0.96 (0.94–0.98) | 12.99 | <0.001 |
| Education                      |             |      |      |
| Any schooling                  | 1.58 (1.12–2.22) | 6.75  | 0.01  |
| No schooling (ref)             |             |      |      |
| Marital status                 |             |      |      |
| Not married or separated       | 1.05 (0.75–1.46) | 0.07  | 0.79  |
| Married (ref)                  |             |      |      |
| Research site                  |             |      |      |
| Landing site                   | 0.92 (0.66–1.30) | 0.21  | 0.65  |
| Island (ref)                   |             |      |      |
| Monthly income                 | 0.92 (0.84–1.00) | 3.86  | 0.05† |
| Occupation                     |             |      |      |
| Fishermen                      | 1.03 (0.67–1.56) | 0.01  | 0.91  |
| Other fishing occupation (ref) |             |      |      |
| Mobility                       |             |      |      |
| Yes                            | 1.65 (1.14–2.40) | 6.92  | 0.01  |
| No (ref)                       |             |      |      |
| Travel time to clinic          | 1.13 (1.01–1.26) | 4.33  | 0.04  |
| Months since HIV diagnosis     | 0.99 (0.94–1.04) | 0.86  | 0.77  |
| Months since ART initiation    | 0.93 (0.87–1.00) | 3.69  | 0.06† |
| Number of pills prescribed per day |          |      |      |
| Twice daily dosing             | 0.37 (0.22–0.62) | 14.28 | <0.001 |
| Once daily dosing (ref)        |             |      |      |
| Alcohol variables              |             |      |      |
| Alcohol use quantity and frequency index | 1.56 (1.27–1.92) | 18.29 | <0.001 |
| Hazardous alcohol use          |             |      |      |
| Yes (AUDIT = / > 8)            | 1.39 (0.98–1.98) | 3.43  | 0.06† |
| No (no drinking and AUDIT <8) (ref) |         |      |      |

Note:
Bold text indicates associations p < .05;
†p < .10;
OR: Odds Ratio;
x² = Wald chi square;
AUDIT = Alcohol Use Disorder Identification Test; ART = antiretroviral treatment; ref = reference group; Monthly income: 1 unit = 50,000 UGX; Travel time to clinic: 1 unit = 30 minutes; Months since HIV diagnosis: 1 unit = 6 months; Months since ART initiation: 1 unit = 6 months.

https://doi.org/10.1371/journal.pone.0216892.t002

Discussion
Despite PLHIV in fishing communities being prioritized for the scale up of test-and-treat initiatives in Uganda, little is known about substance use in this population or its effect on optimal ART adherence; this is the first study to our knowledge to begin to fill this gap in the literature. Among our sample of men enrolled in HIV care, approximately a third reported sub-optimal ART adherence (<95% of ARVs taken as prescribed). Though half the sample reported abstaining from alcohol use altogether, a third of men met criteria for “hazardous”
alcohol use, highlighting the need for alcohol intervention with a portion of men. This is especially needed given the finding that alcohol use was associated with an increased likelihood of missed ARVs among men—with the greatest effect on men on a twice-daily ART regimen.

Our findings add to the broader literature [24, 38] demonstrating greater alcohol consumption is associated with greater likelihood of missed ARVs. We also found men reporting no drinking and men reporting low risk drinking had similar rates of adherence, suggesting the consumption of higher quantities of alcohol may be driving the alcohol-adherence association.

Table 4. Multivariate models testing associations between hazardous drinking and missed antiretroviral medication, Uganda 2016–17, N = 300.

|                    | AOR (95% CI) | x²   | p     |
|--------------------|--------------|------|-------|
| Age                | 0.96 (0.94–0.99) | 9.68 | <0.001|
| Education          |               |      |       |
| Any schooling      | 1.54 (1.08–2.18) | 5.75 | 0.02  |
| No schooling (ref) |               |      |       |
| Monthly income     | 0.73 (0.51–1.04) | 2.97 | 0.09  |
| Number of pills    |               |      |       |
| Twice daily dosing | 0.43 (0.25–0.74) | 9.38 | 0.02  |
| Once daily dosing (ref) |          |      |       |
| Alcohol use quantity and frequency index | 1.60 (1.29–1.97) | 18.97 | <0.001|

Bold text indicates associations p < .05;
'p < .10;
AOR: Adjusted Odds Ratio;
x² = Wald chi square;
ref = reference group.

https://doi.org/10.1371/journal.pone.0216892.t004
However, no direct association was found for hazardous drinking (which encompasses other negative outcomes of drinking in addition to quantity) and missed ARVs. In the literature, there have been mixed findings on the role of alcohol quantity and risk levels on adherence; some studies suggest any drinking regardless of amount or low risk drinking may drive the alcohol-adherence association [31, 38–42], while others suggest higher quantities of drinking drive this association [24, 38, 43]. Though our findings support the latter, more research is needed to better understand the relationship between alcohol use and non-adherence.

Counter to evidence on the advantage of once-daily single tablet regimens for treatment adherence [44], we found a negative direct effect between number of pills prescribed (i.e., once daily vs. twice daily regimens) and adherence; that is, men prescribed once daily regimens reported overall worse adherence than men taking twice daily regimens. However, as demonstrated by the observed interaction between hazardous drinking and number of pills prescribed (see Fig 1), for men classified as hazardous drinkers, those on twice daily dosing had worse adherence compared to those on once daily regimens. One possible explanation that men on twice daily regimens had better adherence overall may be that they were receiving more intensive ART adherence counseling and monitoring since treatment failure on the once daily regimen. Further, men taking twice daily regimens who drink at hazardous levels may have failed on the preferred first line regimen because of alcohol use. For these men, increased adherence counseling and monitoring, which was shown to be working for all other men, may not be addressing their main barrier to adherence–alcohol use. Being switched to twice daily dosing despite increased monitoring may especially increase risk of non-adherence among hazardous drinkers, who may have more difficulty remembering or planning their alcohol consumption around two pills compared to one. Prior studies similarly report regimen complexity is an important factor in alcohol’s influence on adherence [24, 31], reinforcing the benefits of a once daily regimen for men who drink.

Alcohol consumption levels were lower in our sample of men living with HIV compared to prior studies with non-HIV positive fisherfolk [9, 16]. In addition, while several studies have suggested marijuana and khat may be prevalent in these communities [9, 18], very few men reported drug use. While this in part could be explained by underreporting, a qualitative exploration of changes in men’s drinking since diagnosis (reported elsewhere) revealed men in our sample had made significant efforts to reduce their consumption since diagnosis [45]. Yet
hazardous drinking was prevalent among those who do drink; one-third of the overall sample, and two-third of those who drink, were classified as hazardous drinkers on the AUDIT. In addition to the demonstrated negative effects of alcohol on adherence, alcohol’s direct effect on CD4 cell count, and disease progression is dangerous for PLHIV [20, 21, 46], making the level of drinking observed in our sample concerning.

These findings have important implications for clinical practice. First, the integration of screening and brief intervention (SBI) [47] into HIV clinical care with this population may be beneficial, given the observed rates of alcohol consumption and associations between drinking alcohol use and nonadherence. SBI includes universal screening for alcohol misuse, followed by targeted, low-resource, and time-limited (1–2 meetings) efforts to provide information, increase motivation, and teach behavioral change skills to reduce alcohol use [47]. Our findings suggest screening questions should assess both the quantity of alcohol consumed and risk levels, and intervention efforts focused on those screening for higher levels of alcohol use, as opposed to those drinking at lower risk levels, may be most effective. While SBI has gained considerable support in developed settings [48, 49], among the more limited number of studies assessing SBI in sub-Saharan Africa, there is mixed support [50–55]. The successful implementation of SBI and other integrated alcohol-adherence interventions would need to be tailored to the unique context of fishing villages, especially considering significant occupational and structural barriers to HIV care in fishing villages.

The cross-sectional design of our study limits inference of a causal relationship between alcohol and adherence; daily process or event sampling studies are needed to temporally link alcohol-adherence, and quantitatively assess potential mechanisms between the two. Approximately half of our sample reported abstaining from alcohol use and very few men met criteria for harmful drinking/dependence; social desirability may have led to under-reporting of both alcohol use and missed ARVs. The inclusion of biological outcome measures for alcohol use and adherence would have strengthened this study, which relied on self-reported measures. Furthermore, a one-year recall period for the AUDIT may have weakened the observed associations between hazardous drinking and adherence, measured with a 4-day recall period; though our quantity and frequency index provided a measure of current alcohol use. Our alcohol measures also required men to estimate the number of drinks they typically consume. While the interviewer explained to participants the typical size of each type of alcohol assessed during the structured interview, men’s accuracy in this assessment may have varied. In addition, we did not use random sampling to recruit participants; therefore, we cannot generalize our findings to the broader population. Though we did capture men struggling with treatment adherence, by recruiting men directly from the clinic, our sample may over-represent men engaged in HIV care and with better ART adherence.

Conclusions

As global strategies to end the HIV/AIDS epidemic move towards universal testing and treatment for all [3, 56], efforts to optimize ART adherence, especially with high prevalence populations facing significant barriers to HIV care, are needed. Our findings highlight the need for alcohol-reduction interventions for male fisherfolk on ART in order to improve ART adherence and to prevent the known negative health effects of alcohol for PLHIV [46]. The integration of SBI for alcohol reduction into HIV clinical care may be an effective approach to reduce alcohol consumption and improve adherence among men on treatment who drink. Focusing alcohol reduction and adherence intervention efforts on men reporting higher quantities of alcohol consumption may optimize SBI with this population, and alcohol SBI is especially needed for men on twice daily regimens. Future research is needed to understand how to best
tailor and implement an alcohol-reduction intervention given the structural challenges for men in the fishing occupation.

Supporting information

S1 File. Study measures. This questionnaire was administered by an interviewer via Computer-assisted personal interviewing (CAPI) software. (PDF)

S2 File. Study data. This file includes the underlying data for the analyses reported. Variable names correspond with the study measures provided in S1 File. Some information has been removed to de-identify the data and ensure participant confidentiality. (CSV)

Acknowledgments

We thank participants for their time and participation. We are grateful to Mildmay Uganda outreach teams and clinic staff for supporting the implementation of this study. This manuscript is part of Katelyn Sileo’s doctoral dissertation.

Author Contributions

Conceptualization: Katelyn M. Sileo, Rhoda K. Wanyenze, Elizabeth Reed, Jamila K. Stockman, Susan M. Kiene.

Data curation: Katelyn M. Sileo, Williams Kizito, Rhoda K. Wanyenze, Harriet Chemusto, Susan M. Kiene.

Formal analysis: Katelyn M. Sileo, Susan M. Kiene.

Funding acquisition: Katelyn M. Sileo.

Investigation: Katelyn M. Sileo, Williams Kizito, Rhoda K. Wanyenze, Susan M. Kiene.

Methodology: Katelyn M. Sileo, Rhoda K. Wanyenze, Elizabeth Reed, Jamila K. Stockman, Susan M. Kiene.

Project administration: Katelyn M. Sileo, Williams Kizito, Rhoda K. Wanyenze, Harriet Chemusto, William Musoke, Barbara Mukasa.

Resources: Harriet Chemusto, William Musoke, Barbara Mukasa.

Supervision: Katelyn M. Sileo, Williams Kizito, Rhoda K. Wanyenze, Harriet Chemusto, Elizabeth Reed, Jamila K. Stockman, William Musoke, Barbara Mukasa, Susan M. Kiene.

Writing – original draft: Katelyn M. Sileo.

Writing – review & editing: Katelyn M. Sileo, Williams Kizito, Rhoda K. Wanyenze, Harriet Chemusto, Elizabeth Reed, Jamila K. Stockman, William Musoke, Barbara Mukasa, Susan M. Kiene.

References

1. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva, Switzerland: WHO; 2013.

2. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011; 365(6):493–505. https://doi.org/10.1056/NEJMoa1105243 PMID: 21767103
3. World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendation for a Public Health Approach. Second Edition. Geneva: WHO; 2016.

4. Uganda MOH. Addendum to the National Antiretroviral Treatment Guidelines. Kampala, Uganda: Uganda Ministry of Health; 2013.

5. Seeley J, Nakiyangi-Miyo J, Kamali A, Mpendo J, Asiki G, Abaasa A, et al. High HIV incidence and socio-behavioral risk patterns in fishing communities on the shores of Lake Victoria, Uganda. Sex Transm Dis. 2012; 39(6):433–9. https://doi.org/10.1097/OLQ.0b013e318251555d PMID: 22592628

6. Chang LW, Grabowski MK, Seekubugu R, Nalugoda F, Kigozi G, Nanturne B, et al. Heterogeneity of the HIV epidemic in agrarian, trading, and fishing communities in Rakai, Uganda: an observational epidemiological study. Lancet. 2016; 3(3):8.

7. Opio A, Muyonga M, Mulumba N. HIV infection in fishing communities of Lake Victoria basin of Uganda–a cross-sectional sero-behavioral survey. PLoS ONE. 2013; 8(8):e70770. https://doi.org/10.1371/journal.pone.0070770 PMID: 23940638

8. UNAIDS. Country Fact Sheet—Uganda 2016. Retrieved from: http://www.unaids.org/en/regionscountries/countries/uganda. UNAIDS; 2018.

9. Kiwanuka N, Ssetaala A, Nalutaaya A, Mpendo J, Wambuzi M, Nanvubya A, et al. High Incidence of HIV-1 infection in a general population of fishing communities around Lake Victoria, Uganda. PLoS ONE. 2014; 9(5):e94932. https://doi.org/10.1371/journal.pone.0094932 PMID: 24866840

10. Ortego C, Huedo-Medina TB, Llorca J, Sevilla L, Santos P, Rodriguez E, et al. Adherence to highly active antiretroviral therapy (HAART): a meta-analysis. 15(7):1381–96. https://doi.org/10.1007/s10461-011-9942-x PMID: 21468660

11. Cornell M, McIntyre J, Myer L. Men and antiretroviral therapy in Africa: our blind spot. Trop Med Int Health. 2011; 16(7):828–9. https://doi.org/10.1111/j.1365-3156.2011.02767.x PMID: 21418449

12. Shand T, Thomson-de Boor H, van den Berg W, Peacock D, Pascoe L. The HIV blind spot: men and HIV testing, treatment and care in sub-Saharan Africa. IDS Bulletin. 2014; 45(1):53–60. https://doi.org/10.1111/1759-5436.12068

13. Beckham SW, Beyrer C, Luckow P, Doherty M, Naggsie EK, Baral SD. Marked sex differences in all-cause mortality on antiretroviral therapy in low- and middle-income countries: a systematic review and meta-analysis. J Int AIDS Soc. 2016; 19(1):21106. https://doi.org/10.7448/IAS.19.1.21106 PMID: 27834182

14. Sileo K, Kintu M, Chanes-Mora P, Kiene S. “Such behaviors are not in my home village, I got them here”: a qualitative study of the influence of contextual factors on alcohol and HIV risk behaviors in a fishing community on Lake Victoria, Uganda. AIDS Behav. 2016; 20(3):537–47. https://doi.org/10.1007/s10461-015-1077-z PMID: 25921303

15. Seeley JA, Allison EH. HIV/AIDS in fishing communities: challenges to delivering antiretroviral therapy to vulnerable groups. AIDS Care. 2005; 17(6):688–97. https://doi.org/10.1080/0954012041233136696 PMID: 16036255

16. Tumwesigye NM, Atuyambe L, Wanyenze RK, Kibira SP, Li Q, Wabwire-Mangen F, et al. Alcohol consumption and risky sexual behaviour in the fishing communities: evidence from two fish landing sites on Lake Victoria in Uganda. BMC Public Health. 2012; 12:12.

17. Smolak A. A meta-analysis and systematic review of HIV risk behavior among fishermen. AIDS Care. 2013; 26(3):282–91. https://doi.org/10.1080/09540120412331336696 PMID: 16036255

18. Asiki G, Mpendo J, Abaasa A, Agaba C, Nanvubya A, Nielsen L, et al. HIV and syphilis prevalence and associated risk factors among fishing communities of Lake Victoria, Uganda. Sex Transm Dis. 2011; 87(6):511–5.

19. Jenkins RA. Getting to Zero: We Can’t Do It Without Addressing Substance Use. AIDS Education and Prevention. 2018; 30(3):225–31. https://doi.org/10.1521/aap.2018.30.3.225 PMID: 29969312

20. Samet JH, Cheng DM, Libman H, Nunes DP, Alperen JK, Saltz R. Alcohol consumption and HIV disease progression. J Acquir Immune Defic Syndr. 2007; 46(2):194–9. https://doi.org/10.1097/QAI.0b013e318142abb PMID: 17667330

21. Kahler CW, Liu T, Cioe PA, Bryant V, Pinkston MM, Kojic EM, et al. Direct and indirect effects of heavy alcohol use on clinical outcomes in a longitudinal study of HIV patients on ART. AIDS Behav. 2017; 21(7):1825–1835. https://doi.org/10.1007/s10461-016-1474-y PMID: 27392417

22. Baum MK, Rafie C, Lai S, Sales S, Page JB, Campa A. Alcohol Use Accelerates HIV Disease Progression. AIDS Res Hum Retrovir. 2010; 26(5):511–8. https://doi.org/10.1089/aid.2009.0211 PMID: 20455765
23. Kader R, Govender R, Seedat S, Koch JR, Parry C. Understanding the impact of hazardous and harmful use of alcohol and/or other drugs on ARV adherence and disease progression. PLOS ONE. 2015; 10(5):e0125088. doi:10.1371/journal.pone.0125088 PMID: 25933422

24. Hendershot CS, Stoner SA, Pantalone DW, Simoni JM. Alcohol use and antiretroviral adherence: review and meta-analysis. J Acquir Immune Defic Syndr. 2009; 52(2):180–202. doi:10.1097/QAI.0b013e3181b18b6e PMID: 19668086

25. Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG. The alcohol use disorders identification test: guidelines for use in primary care. Geneva: World Health Organization; 2001.

26. Kiwanuka N, Ssetaala A, Ssekandi I, Nalutaaya A, Kitandwe PK, Ssempiira J, et al. Population attributable fraction of incident HIV infections associated with alcohol consumption in fishing communities around Lake Victoria, Uganda. PLoS One. 2017 16; 12(2):e0171200. doi:10.1371/journal.pone.0171200 PMID: 28207844

27. Bogart LM, Naigino R, Maistrellis E, et al. Barriers to Linkage to HIV Care in Ugandan Fisherman Communities: A Qualitative Analysis. AIDS Behav. 2016; 20(10):2464–2476. doi:10.1007/s10461-016-1331-z PMID: 26961380

28. Tumwesigye NM, Wanyenze RK, Greenfield TK. Intoxication before last sexual encounter and HIV risk behavior among men and women in Uganda: evidence from a nationwide survey. Int J Alcohol Drug Res. 2012; 1(1):17. PMID: 23071484

29. Wandera B, Tumwesigye NM, Nankabirwa JL, Kambuug AD, Parkes-Ratanshi R, Mafigiri DK, et al. Alcohol consumption among HIV-infected persons in a large urban HIV clinic in Kampala Uganda: a constellation of harmful behaviors. PLoS ONE. 2015; 10(5):e0126236. doi:10.1371/journal.pone.0126236 PMID: 25962171

30. Hahn JA, Emenyonu N, Fatch R, Muyindike WR, Kekibina A, Carrico AW, et al. Declining and rebounding unhealthy alcohol consumption during the first year of HIV care in rural Uganda, using phosphatidylyethanol to augment self-report. Addiction. 2016; 111(2):272–9. doi:10.1111/add.13173 PMID: 26381193

31. Parsons JT, Rosof E, Mustanski B. The temporal relationship between alcohol consumption and HIV-medications adherence: a multilevel model of direct and moderating effects. Health Psychol. 2008; 27(5):628–37. doi:10.1037/a0012664 PMID: 18823189

32. The World Health Organization (WHO). The Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Care. Geneva: WHO; 2001.

33. National Institute on Drug Abuse (NIDA). NIDA-Modified ASSIST V2.0. Retrieved from: https://www.drugabuse.gov/sites/default/files/files/QuickScreen_Updated_2013(1).pdf.

34. Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG adherence instruments. AIDS Care. 2000; 12(3):255–66. doi:10.1080/0954012005004289 PMID: 10928201

35. Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, Kityo C, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS. 2007; 21(8):965–71 doi:10.1097/QAD.0b013e32802e6bfa PMID: 17457090

36. Howell DC. Statistical methods in human sciences. New York: Wadsworth; 1998.

37. Tumwesigye NM, Rogers K. Gender, Alcohol, and Culture International Study (GENACIS) in Uganda; Uganda Country Report. 2003.

38. Sileo KM, Simbayi LC, Abrams A, Cloete A, Kiene SM. The role of alcohol use in antiretroviral adherence among individuals living with HIV in South Africa: event-level findings from a daily diary study. Drug Alcohol Depend. 2016; 167:103–11. doi:10.1016/j.drugalcdep.2016.07.028 PMID: 27567968

39. Sankar A, Wunderlich T, Neufeld S, M. L. Sero-positive African Americans' beliefs about alcohol and their impact on antiretroviral adherence. AIDS Behav. 2007; 11:195–203. doi:10.1007/s10461-006-9144-0 PMID: 16799842

40. Tucker JS, Burnam MA, Sherbourne CD, Kung FY, Gifford AL. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med. 2003; 114(7):573–80. PMID: 12753881

41. Samet JH, Horton NJ, Meli S, Freedberg KA, Palepu A. Alcohol consumption and antiretroviral adherence among HIV-infected persons with alcohol problems. Alcohol Clin Exp Res. 2004; 28(4):572. PMID: 15100608

42. Samet JH, Cheng DM, Libman H, Nunes DP, Alperen JK, Saizt R. Alcohol consumption and HIV disease progression. J Acquir Immune Defic Syndr. 2007; 46(2):194–9. doi:10.1097/QAI.0b013e318142aabb PMID: 17667330
43. Braithwaite RS, Conigliaro J, McGinnis KA, Maisto SA, Bryant K, Justice AC. Adjusting alcohol quantity for mean consumption and intoxication threshold improves prediction of nonadherence in HIV patients and HIV-negative controls. Alcohol Clin Exp Res. 2008; 32(9):1645–51. https://doi.org/10.1111/j.1530-0277.2008.00732.x PMID: 18616666

44. Truong WR, Schafer JJ, Short WR. Once-daily, single-tablet regimens For the treatment of HIV-1 infection. P T. 2015; 40(1):44–55. PMID: 25628507

45. Sileo KM, Kizito W, Wanyenze RK, Chemusto H, Musoke W, Mukasa B, et al. A qualitative study on alcohol consumption and HIV treatment adherence among men living with HIV in Ugandan fishing communities. AIDS Care. 2019; (1):35–40. https://doi.org/10.1080/09540121.2018.1524564 PMID: 30241440

46. Braithwaite RS, Bryant KJ. Influence of alcohol consumption on adherence to and toxicity of antiretroviral therapy and survival. Alcohol Res Health. 2010; 33(3):280–7. PMID: 23584069

47. Babor TF, McRee BG, Kassabauer PA, Grimaldi PL, Ahmed K, Bray J. Screening, brief intervention, and referral to treatment (SBIRT). Substance Abuse. 2007; 28(3):7–30. https://doi.org/10.1300/J465v28n03_03 PMID: 18077300

48. Kaner EF, Dickinson HO, Beyer FR. Effectiveness of brief alcohol interventions in primary care populations (review). Cochrane Database Syst Rev. 2007; 2.

49. Carney T, Myers BJ, Louw J, Okwundu CI. Brief school-based interventions and behavioural outcomes for substance-using adolescents. Cochrane Database Syst Rev. 2016(1):Cd008869. https://doi.org/10.1002/14651858.CD008869.pub3 PMID: 26787125

50. Mertens JR, Ward CL, Bresick GF, Broder T, Weiner CM. Effectiveness of nurse-practitioner-delivered brief motivational intervention for young adult alcohol and drug use primary care in South Africa: a randomized clinical trial. Alcohol Alcohol. 2014; 49(4):430–8. https://doi.org/10.1093/alcalc/agu030 PMID: 24899076

51. L'Engle KL, Mwarogo P, Kingola N, Sinkele W, Weiner DH. A randomized controlled trial of a brief intervention to reduce alcohol use among female sex workers in Mombasa, Kenya. J Acquir Immune Defic Syndr. 2014; 67(4):446–53. https://doi.org/10.1097/QAI.0000000000000335 PMID: 25197826

52. Pengpid S, Peltzer K, van der Heever H, Skaal L. Screening and brief interventions for hazardous and harmful alcohol use among university students in South Africa: results from a randomized controlled trial. International journal of environmental research and public health. 2013; 10(5):2043–57. https://doi.org/10.3390/ijerph10052043 PMID: 23698697

53. Peltzer K, Naidoo P, Louw J, Matsike G, Zuma K, McHunu G, et al. Screening and brief interventions for hazardous and harmful alcohol use among patients with active tuberculosis attending primary public care clinics in South Africa: results from a cluster randomized controlled trial. BMC Public Health. 2013; 13:699. https://doi.org/10.1186/1471-2458-13-699 PMID: 23902931

54. Pengpid S, Peltzer K, Skaal L, Van der Heever H. Screening and brief interventions for hazardous and harmful alcohol use among hospital outpatients in South Africa: results from a randomized controlled trial. BMC Public Health. 2013; 13:644. https://doi.org/10.1186/1471-2458-13-644 PMID: 23944552

55. Rendall-Mkosi K, Morojele N, London L, Moodley S, Singh C, Girdler-Brown B. A randomized controlled trial of motivational interviewing to prevent risk for an alcohol-exposed pregnancy in the Western Cape, South Africa. Addiction. 2013; 108(4):725–32. https://doi.org/10.1111/add.12081 PMID: 23216868

56. UNAIDS. 90-90-90: An ambitious treatment target to help end the AIDS epidemic. Geneva: UNAIDS; 2014.